Back to top
more

SOPHiA GENETICS (SOPH)

(Real Time Quote from BATS)

$4.65 USD

4.65
24,318

+0.01 (0.22%)

Updated May 15, 2024 11:13 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (142 out of 250)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for SOPH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for SOPHiA GENETICS SA falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 123 179 265 97 18
Receivables 14 7 6 6 8
Notes Receivable 0 0 0 0 0
Inventories 6 5 6 3 4
Other Current Assets 5 6 6 3 4
Total Current Assets 148 196 283 110 34
Net Property & Equipment 7 7 5 2 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 2 2 2 2 0
Intangibles 27 20 16 13 10
Deposits & Other Assets 6 4 4 1 1
Total Assets 206 244 320 132 52
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 5 6 7 6 5
Current Portion Long-Term Debt 0 0 0 3 2
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 18 15 16 9 7
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 9 3 4 3 4
Total Current Liabilities 36 27 29 22 19
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 2
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 3 3 5 7 5
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 55 44 45 32 29
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 4 3 3 2 2
Capital Surplus 472 472 471 227 119
Retained Earnings -378 -299 -211 -138 -98
Other Equity 54 24 13 8 -1
Treasury Stock 1 0 0 0 0
Total Shareholder's Equity 151 200 275 101 22
Total Liabilities & Shareholder's Equity 206 244 320 132 52
Total Common Equity 151 200 275 101 22
Shares Outstanding NA 63.30 63.30 NA NA
Book Value Per Share 0.00 3.16 4.35 0.00 0.00

Fiscal Year End for SOPHiA GENETICS SA falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 104 123 133 149 162
Receivables 11 14 10 10 10
Notes Receivable 0 0 0 0 0
Inventories 6 6 5 5 4
Other Current Assets 4 5 5 5 6
Total Current Assets 125 148 153 169 182
Net Property & Equipment 7 7 7 8 7
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 2 2 2 2 2
Intangibles 26 27 24 23 21
Deposits & Other Assets 6 6 5 6 5
Total Assets 180 206 206 223 232
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 6 5 6 7 8
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 13 18 13 14 10
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 8 9 7 8 8
Total Current Liabilities 30 36 29 32 29
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 3 4 4 3
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 48 55 47 52 47
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 4 4 4 4 3
Capital Surplus 472 472 472 472 472
Retained Earnings -391 -378 -354 -340 -319
Other Equity 48 54 37 36 28
Treasury Stock 1 1 1 1 0
Total Shareholder's Equity 132 151 158 172 185
Total Liabilities & Shareholder's Equity 180 206 206 223 232
Total Common Equity 132 151 158 172 185
Shares Outstanding 65.20 NA NA 63.30 63.30
Book Value Per Share 2.03 0.00 0.00 2.71 2.92